Full Text View
Tabular View
Study Results
Related Studies
Randomized Phase II Study of Hepatitis C Immune Globulin Intravenous (Human), Civacir(TM), in Liver Transplantation
This study has been terminated.
( New sponsor's decision to pursue a redesigned clinical study )
Study NCT00473824   Information provided by Biotest Pharmaceuticals Corporation

First Received on May 14, 2007.   Last Updated on May 7, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sequelae of Viral Hepatitis
Transplantation Infection
Evidence of Liver Transplantation
Additional conditions recognized in this trial
Hepatitis
Hepatitis A
Hepatitis C
More general conditions related to this trial
Digestive System Diseases
Enterovirus Infections
Flaviviridae Infections
Hepatitis, Viral, Human
Liver Diseases
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Additional drug interventions recognized in this trial
Antibodies
Immunoglobulins
Immunoglobulins, Intravenous
Rho(D) Immune Globulin
More general drug interventions related to this trial
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Sponsors listed in this trial
Biotest Pharmaceuticals Corporation


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services